Vasopressin-receptor antagonists

Future Cardiology

Volumn 6, Issue 4, 2010, Pages 523-534

  Hoorn, Ewout J ^a   Zietse, Robert ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

aquaresis; congestive heart failure; hyponatremia; liver cirrhosis; mortality; natriuresis; syndrome of inappropriate antidiuretic hormone secretion; vasopressin 2 receptor

Indexed keywords

AQUAPORIN 2; AQUAPORIN 3; AQUAPORIN 4; AQUILDA; ARGIPRESSIN; CARBAMAZEPINE; CLARITHROMYCIN; CONIVAPTAN; CYTOCHROME P450 3A4; DIGOXIN; GLYCOPROTEIN P; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LIXIVAPTAN; MOZAVAPTAN; OXYTOCIN; PLACEBO; RIFAMPICIN; RITONAVIR; SAMSCA; SATAVAPTAN; SECRETIN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOWN REGULATION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; ORTHOSTATIC HYPOTENSION; POLLAKISURIA; POLYDIPSIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; THIRST; TREATMENT OUTCOME; VASOPRESSIN BLOOD LEVEL; WATER RETENTION; XEROSTOMIA; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPONATREMIA; VASOPRESSINS;

EID: 77954508208     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.22     Document Type: Review

References (69)

1. Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371(9624), 1624-1632 (2008).
2. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res. 170, 473-512 (2008).
3. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA: Aquaporins in the kidney: from molecules to medicine. Physiol. Rev. 82(1), 205-244 (2002).
4. Finley JJT, Konstam MA, Udelson JE: Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 118(4), 410-421 (2008).
5. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH: Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N. Engl. J. Med. 310(6), 347-352 (1984).
6. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA: Dilutional hyponatremia in patients with cirrhosis and ascites. Arch. Intern. Med. 162(3), 323-328 (2002).
7. Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N. Engl. J. Med. 319(17), 1127-1134 (1988).
8. Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N. Engl. J. Med. 319(16), 1065-1072 (1988).
9. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D: Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48(1), 204-213 (2008).
10. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B: Copeptin in the differential diagnosis of hyponatremia. J. Clin. Endocrinol. Metab. 94(1), 123-129 (2009).
11. Cheng CY, Chu JY, Chow BK: Vasopressin-independent mechanisms in controlling water homeostasis. J. Mol. Endocrinol. 43(3), 81-92 (2009).
12. Hoorn EJ, Lindemans J, Zietse R: Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol. Dial. Transplant. 21(1), 70-76 (2006).
13. Hoorn EJ, Zietse R: Hyponatremia revisited: translating physiology to practice. Nephron. Physiol. 108(3), P46-P59 (2008).
14. Ellison DH, Berl T: Clinical practice. The syndrome of inappropriate antidiuresis. N. Engl. J. Med. 356(20), 2064-2072 (2007).
15. Sawyer WH, Pang PK, Seto J, McEnroe M, Lammek B, Manning M: Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 212(4490), 49-51 (1981).
16. Manning M, Olma A, Klis W et al.: Carboxy terminus of vasopressin required for activity but not binding. Nature 308(5960), 652-653 (1984).
17. Ruffalo RR, Brooks DP, Huffman WF, Poste G: From vasopressin antagonist to agonist. A saga of surprise. Drug News Perspect. 4, 217-222 (1991).
18. Manning M, Przybylski JP, Olma A et al.: No requirements of cyclic conformation of antagonists in binding to vasopressin receptors. Nature 329(6142), 839-840 (1987).
19. Ros J, Fernandez-Varo G, Munoz-Luque J et al.: Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br. J. Pharmacol. 146(5), 654-661 (2005).
20. Greenberg A, Verbalis JG: Vasopressin receptor antagonists. Kidney Int. 69(12), 2124-2130 (2006).
21. Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M: Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J. Pharmacol. Exp. Ther. 316(2), 564-571 (2006).
22. Ohnishi A, Orita Y, Okahara R et al.: Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. 92(6), 2653-2659 (1993).
23. Costello-Boerrigter LC, Boerrigter G, Burnett Jr. JC: Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med. Clin. North Am. 87(2), 475-491 (2003).
24. Goldsmith SR: Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am. J. Med. 119(7 Suppl. 1), S93-S96 (2006).
25. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor V1a/V2 antagonist [corrected]. Cardiovasc. Drug Rev. 25(3), 261-279 (2007).
26. Dixon MB, Lien YH: Tolvaptan and its potential in the treatment of hyponatremia. Ther. Clin. Risk Manag. 4(6), 1149-1155 (2008).
27. Chen S, Jalandhara N, Batlle D: Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat. Clin. Pract. Nephrol. 3(2), 82-95 (2007).
28. Costello-Boerrigter LC, Boerrigter G, Burnett Jr. JC: Pharmacology of vasopressin antagonists. Heart Fail. Rev. 14(2), 75-82 (2009).
29. Udelson JE, Smith WB, Hendrix GH et al.: Acute hemodynamic effects of conivaptan, a dual V(1a) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104(20), 2417-2423 (2001).
30. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am. J. Med. Sci. 337(1), 28-36 (2009).
31. Ghali JK, Koren MJ, Taylor JR et al.: Efficacy and safety of oral conivaptan: a V1a/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 91(6), 2145-2152 (2006).
32. Gheorghiade M, Gottlieb SS, Udelson JE et al.: Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 97(7), 1064-1067 (2006).
33. Schrier RW, Gross P, Gheorghiade M et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355(20), 2099-2112 (2006).
34. Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37(1), 182-191 (2003).
35. Zeltser D, Rosansky S, Van Rensburg H, Verbalis JG, Smith N: Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol. 27(5), 447-457 (2007).
36. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW: Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J. Am. Coll. Cardiol. 47(8), 1615-1621 (2006).
37. Costello-Boerrigter LC, Smith WB, Boerrigter G et al.: Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. 290(2), F273-F278 (2006).
38. Gheorghiade M, Gattis WA, O'Connor CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291(16), 1963-1971 (2004).
39. Gheorghiade M, Niazi I, Ouyang J et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107(21), 2690-2696 (2003).
40. Konstam MA, Gheorghiade M, Burnett Jr. JC et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297(12), 1319-1331 (2007).
41. Udelson JE, McGrew FA, Flores E et al.: Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 49(22), 2151-2159 (2007).
42. Gerbes AL, Gulberg V, Gines P et al.: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124(4), 933-939 (2003).
43. Soupart A, Gross P, Legros JJ et al.: Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin. J. Am. Soc. Nephrol. 1(6), 1154-1160 (2006).
44. Hoorn EJ, Hoffert JD, Knepper MA: Combined proteomics and pathways analysis of collecting duct reveals a protein regulatory network activated in vasopressin escape. J. Am. Soc. Nephrol. 16(10), 2852-2863 (2005).
45. Steiner M, Phillips MI: Renal tubular vasopressin receptors downregulated by dehydration. Am. J. Physiol. 254(3 Pt 1), C404-C410 (1988).
46. Tian Y, Sandberg K, Murase T, Baker EA, Speth RC, Verbalis JG: Vasopressin V2 receptor binding is down-regulated during renal escape from vasopressin-induced antidiuresis. Endocrinology 141(1), 307-314 (2000).
47. Gheorghiade M, Rossi JS, Cotts W et al.: Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch. Intern. Med. 167(18), 1998-2005 (2007).
48. Kim WR, Biggins SW, Kremers WK et al.: Hyponatremia and mortality among patients on the liver-transplant waiting list. N. Engl. J. Med. 359(10), 1018-1026 (2008).
49. Decaux G: Is asymptomatic hyponatremia really asymptomatic? Am. J. Med. 119(7 Suppl. 1), S79-S82 (2006).
50. Verbalis JG, Barsony J, Sugimura Y et al.: Hyponatremia-induced osteoporosis. J. Bone Miner. Res. 25(3), 554-563 (2010).
51. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G: Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 101(7), 583-588 (2008).
52. Hoorn EJ, Van Der Lubbe N, Zietse R: SIADH and hyponatraemia: why does it matter? NDT Plus 2(Suppl. 3), III5-III11 (2009).
53. Decaux G: Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am. J. Med. 110(7), 582-584 (2001).
54. Hoorn EJ, Zietse R: Tolvaptan for hyponatremia. N. Engl. J. Med. 356(9), 961; author reply 962-963 (2007).
55. Laureno R, Karp BI: Myelinolysis after correction of hyponatremia. Ann. Intern. Med. 126(1), 57-62 (1997).
56. Boscoe A, Paramore C, Verbalis JG: Cost of illness of hyponatremia in the United States. Cost Eff. Resour. Alloc. 4, 10 (2006).
57. Zietse R, Van Der Lubbe N, Hoorn EJ: Current and future treatment options in SIADH. NDT Plus 2(Suppl. 3), III12-III19 (2009).
58. Hoorn EJ, Halperin ML, Zietse R: Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM 98(7), 529-540 (2005).
59. Van Der Hoek J, Hoorn EJ, De Jong GM, Janssens EN, De Herder WW: Severe hyponatremia with high urine sodium and osmolality. Clin. Chem. 55(11), 1905-1908 (2009).
60. Van Der Lubbe N, Thompson CJ, Zietse R, Hoorn EJ: The clinical challenge of SIADH-three cases. NDT Plus 2(Suppl. 3), III20-III24 (2009).
61. Clayton JA, Le Jeune IR, Hall IP: Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM 99(8), 505-511 (2006).
62. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L: Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J. Am. Soc. Nephrol. 19(9), 1721-1731 (2008).
63. Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C: Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J. Am. Soc. Nephrol. 18(2), 606-612 (2007).
64. Murphy T, Dhar R, Diringer M: Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit. Care 11(1), 14-19 (2009).
65. Josiassen RC, Goldman M, Jessani M et al.: Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia. Biol. Psychiatry 64(12), 1097-1100 (2008).
66. Rianthavorn P, Cain JP, Turman MA: Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH. Pediatr. Nephrol. 23(8), 1367-1370 (2008).
67. Costello-Boerrigter LC, Boerrigter G, Burnett Jr. JC: V2 receptor antagonism with tolvaptan in heart failure. Expert Opin. Investig. Drugs 16(10), 1639-1647 (2007).
68. Vaprisol: US FDA professional drug information (2008) www.drugs.com/pro/vaprisol Accessed 21 January 2010
69. Samsca: US FDA professional drug information (2009) www.drugs.com/pro/ samsca Accessed 21 January 2010